# Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

> **NCT06021951** · PHASE4 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy Lactating Women

## Interventions

- **DRUG:** Bempedoic Acid 180 MG Oral Tablet
- **DRUG:** Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet

## Key facts

- **NCT ID:** NCT06021951
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-04
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-03-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06021951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06021951, "Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06021951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*